Carbestrol
Carbestrol (developmental code names NSC-19962, ORF-2166) is a synthetic, nonsteroidal estrogen of the cyclohexenecarboxylic acid group and seco analogue of doisynolic acid that was described in the literature in 1956 and developed for the treatment of prostate cancer in the 1960s but was never marketed.[1][2][3][4]
 | |
| Clinical data | |
|---|---|
| Other names | NSC-19962; ORF-2166 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H22O3 |
| Molar mass | 274.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 516–. ISBN 978-1-4757-2085-3.
- ARDUINO LJ (1964). "Carbestrol (NSC-19962) Treatment of Patients with Prostatic Carcinoma-Preliminary Report". Cancer Chemother Rep. 39: 67–75. PMID 14201278.
- Kogler J, Hill G, Sedransk N, Cole DR, Weiss AJ, Wilson W (1972). "Phase II study of carbestrol (NSC-19962) in patients with solid tumors". Cancer Chemother Rep. 56 (5): 641–7. PMID 4652590.
- Raymond Eller Kirk; Donald Frederick Othmer (1980). Encyclopedia of chemical technology. Wiley. p. 672. ISBN 978-0-471-02065-3.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.